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Summary
Wedemonstrate that PTEN loss causes reducedNKX3.1 expression in bothmurine andhumanprostate cancers. Restoration
ofNkx3.1 expression in vivo inPten null epithelium leads to decreased cell proliferation, increased cell death, and prevention
of tumor initiation.Whereasandrogen receptor (AR) positively regulatesNKX3.1expression,NKX3.1negativelymodulatesAR
transcription and consequently the AR-associated signaling events. Consistent with its tumor suppressor functions, NKX3.1
engages cell cycle and cell death machinery via association with HDAC1, leading to increased p53 acetylation and half-life
throughMDM2-dependentmechanisms. Importantly, overexpression ofNkx3.1 has little effect onPtenwild-type epithelium,
suggesting that PTEN plays a predominant role in PTEN-NKX3.1 interplay. Manipulating NKX3.1 expression may serve as
a therapeutic strategy for treating PTEN-deficient prostate cancers.Introduction
Prostate cancer is the second leading cause of cancer-related
death in males (Gregorakis et al., 1998; McDavid et al., 2004).
Its development proceeds through a series of defined steps, in-
cluding prostatic intraepithelial neoplasia (PIN), invasive cancer,
and hormone-dependent or -independent metastasis. Although
different stages of prostate cancer have been well defined histo-
logically, relatively little is known about the molecular mecha-
nisms contributing to the initiation and progression of prostate
cancer.
The PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10) tumor suppressor gene is frequently mutated in
human cancers (Dahia, 2000; Maehama et al., 2001; Parson
et al., 1998). Themajor function of PTEN relies on its phosphatase
activity toward PIP3 (phosphatidyl inositol 3,4,5-triphosphate)
and, consequently, antagonism of the PI3K (phosphatidylinositolCANCER CELL 9, 367–378, MAY 2006 ª2006 ELSEVIER INC. DOI 10.1013-kinase) signaling pathway (Di Cristofano et al., 2001; Maehama
et al., 2001). Loss of PTEN function results in accumulation of
PIP3 and activation of its downstream effectors, such as AKT/
PKB (Maehama et al., 2001). AKT, a serine/threonine protein
kinase, phosphorylates key intermediate signaling molecules,
leading to increased cell metabolism, growth, survival, and inva-
siveness, all hallmarks of cancer (Di Cristofano et al., 2001;
Hanahan and Weinberg, 2000; Vivanco and Sawyers, 2002).
PTEN alteration is strongly implicated in prostate cancer de-
velopment, as mutations of the PTEN gene are found in 30%
of primary prostate cancers (Dahia, 2000; Sellers and Sawyers,
2002) and 63% of metastatic prostate tissue samples (Suzuki
et al., 1998). Thus, PTEN mutations are among the most fre-
quent genetic alterations in human prostate cancer. As PTEN-
controlled signaling pathways are frequently altered in human
prostate cancers, inhibiting the resultant signaling aberrations
will likely serve as promising targets for therapeutic strategiesS I G N I F I C A N C E
Gene expression profiling of mouse tumor models or human cancers has identified many dysregulated genes that may contribute to
tumor development. These wealthy data sets, upon functional validation, may help in elucidating the molecular mechanisms under-
lying tumorigenesis and providing potential novel targets for cancer therapies. Using a powerful prostate epithelial tissue reconstitution
assay, we demonstrated the importance of NKX3.1 in prostate cancer initiation caused by PTEN loss. Our finding emphasizes the co-
operative effects between ubiquitously expressed PTEN tumor suppressor genes and prostate-specific expressed NKX3.1 in prostate
cancer development.Our study further indicates that validationof candidategenes usingmousemodels canyield valuablemolecular
insights that impact human cancer research.6/j.ccr.2006.03.031 367
A R T I C L E(DeMarzo et al., 2003; Sellers and Sawyers, 2002; Vivanco and
Sawyers, 2002).
We and others have developed murine models of prostate
cancers by deleting the Pten tumor suppressor gene specifically
in the prostatic epithelium (Chen et al., 2005; Ma et al., 2005;
Trotman et al., 2003; Wang et al., 2003). The Pten prostate can-
cer model recapitulates many features of the disease progres-
sion seen in humans with defined kinetics: initiation of prostate
cancer with PIN lesions, followed by progression to locally inva-
sive adenocarcinoma, and subsequent metastasis (Wang et al.,
2003). Similar to human cancer, Pten null murine prostate can-
cers regress in response to androgen ablation therapy but sub-
sequently relapse and proliferate in the absence of androgens
(Wang et al., 2003).
Global assessment of molecular changes caused by homozy-
gous Pten deletion identified key genes known to be relevant to
humanprostate cancer, including those ‘‘signature’’ genesasso-
ciatedwith humancancermetastasis (Wang et al., 2003). Among
the genes that are downregulated in Pten null prostate cancer is
Nkx3.1, a homeobox gene specifically expressed in the prostate
epithelium. NKX3.1 is one of the earliestmarkers for prostate de-
velopment and is continuously expressed at all stages during
prostate development and in adulthood (Bhatia-Gaur et al.,
1999). Human NKX3.1 maps to chromosome 8p21, a region
that frequently undergoes loss of heterozygosity (LOH) at early
stages of prostate carcinogenesis (He et al., 1997; Voeller
et al., 1997). Nkx3.1 mutant mice develop prostatic hyperplasia
and dysplasia. However, these early lesions failed to progress
to metastatic cancers (Abdulkadir et al., 2002; Bhatia-Gaur
et al., 1999), consistentwith a role forNkx3.1 inactivation in pros-
tate cancer initiation.
In this study, we employed a dissociated prostatic epithelial
regeneration system to directly test the significance of Nkx3.1
loss in Pten null prostate cancer formation. Our data show that
NKX3.1 plays an important role in prostate cancer initiation
caused by PTEN loss and that forced Nkx3.1 expression pre-
vents Pten null prostate cancer initiation and progression.
Thus, decreased Nkx3.1 expression contributes to prostate
cancer development caused by PTEN loss.
Results
PTEN loss leads to reduced NKX3.1 expression in both
murine and human prostate cancers
Our previous gene expression profiling analysis revealed that
Nkx3.1 mRNA level is downregulated in the Pten null prostate
cancers (Wang et al., 2003). In this study, consecutive sections
of ventral prostate lobe from 4-week-old (4W) Pten conditional
knockout animals were probed with antibodies to either
NKX3.1 or phospho-AKT (P-AKT/Ser 473) (Figure 1A). In the ac-
ini where P-AKT levels are low, intense NKX3.1 staining can be
observed (Figure 1A, arrows). In contrast, areas with high P-AKT
are either low or negative for NKX3.1 staining (Figure 1A, arrow-
heads). Since increased AKT phosphorylation is a consequence
of PTEN loss (Figure S1 in the Supplemental Data available with
this article online), these staining patterns suggest that Nkx3.1
downregulation is an early event linked to Pten deletion and
prostate cancer initiation.
To test whether PTEN-regulated Nkx3.1 expression can be
observed in human prostate cancers, we conducted double im-
munofluorescent analysis of PTEN and NKX3.1, using human368prostate tissue microarrays (Rocchi et al., 2004). Among 153
samples surveyed (see Experimental Procedures), positive
PTEN expression was significantly correlated with NKX3.1
staining, whereas PTEN loss was associated with decreased
NKX3.1 staining (Figure 1C; p < 0.01). Photos from two repre-
sentative samples are shown in Figure 1B. Therefore, PTEN
loss leads to decreased NKX3.1 expression in both human
and murine prostate cancers, implying that NKX3.1 may serve
Figure 1. PTEN loss leads to decreased NKX3.1 protein levels in both murine
and human prostate epithelium
A: Consecutive sections of 4-week-old Pten mutant prostates were probed
for NKX3.1 (left) and phospho-AKT (Ser 473) (P-AKT, right) expression. Arrows
and arrowheads point to the same duct. Note that NKX3.1 expression re-
versely correlates with P-AKT staining.
B: High-magnification views of two representative samples from human
prostate cancer tissue microarray are shown here. Upper panels: H&E stain-
ing; middle and lower panels: double immunofluorescent staining using
anti-PTEN (middle) and anti-NKX3.1 (lower) antibodies. Insert: high-power
overlay of NKX3.1 and DAPI staining showing NKX3.1 nuclear localization.
C: Correlation of PTEN and NKX3.1 protein levels in 153 human prostate sam-
ples. SPSS liner regression was used to analyze data, and the standardized
coefficient value was 0.52 (p < 0.01 level; n = 153).CANCER CELL MAY 2006
A R T I C L Eas an important regulator downstream of PTEN-controlled sig-
naling pathway in prostate cancer development.
Forced Nkx3.1 expression in Pten null epithelium
using an exogenous promoter
Several mechanisms have been proposed for loss of NKX3.1 ex-
pression in human prostate cancers, including both transcrip-
tional and posttranscriptional regulations (Asatiani et al., 2005;
Bowenet al., 2000;Heet al., 1997;Korkmazet al., 2004;Ornstein
et al., 2001; Voeller et al., 1997). To understand how PTEN con-
trols NKX3.1 expression and to evaluate the functional relevance
of Nkx3.1 downregulation in Pten null prostate cancer initiation,
we employed a dissociated prostate cell regeneration method
(Xin et al., 2003, 2005) to test (1) whether we can restore NKX3.1
expression in Pten null epithelium to a level comparable to the
wild-type (wild-type) by using an exogenous promoter, and (2)
theconsequenceof forcedNkx3.1expression inPtennullprostate
epithelium. In order to circumvent the low transfection efficiency
of mouse prostate epithelium, we cloned Flag-tagged Nkx3.1
into a lentiviral vector (Xin et al., 2003, 2005) in which Nkx3.1
expression is driven by the ubiquitin promoter followed by an
IRES-eGFP expression cassette (Figure 2A) (Lois et al., 2002).
NKX3.1 expression can be detected indirectly via eGFP expres-
sion (Figure 2B, left panels) and by Western blot analysis of
transfected 293T cells using total protein lysate (Figure 2B,
upper row in the right panel) or eGFP-sorted cells (Figure 2B,
middle row in the right panel) with an anti-Flag antibody.
We then infected epithelium from4WPten null mice (Mut), cor-
responding to the hyperplastic stage, and the epithelium from
their wild-type littermates with Nkx3.1 expressing (NKX3.1
group) or control lentivirus (GFP group). Infected epithelium
was then mixed with mesenchyme isolated from embryonic
day 16 wild-type urogenital sinus mesenchyme (UGSM) and
grafted under the renal capsule of CB17SCID/SCID mice and prop-
agated for 6 weeks. Low but detectable levels of PTEN expres-
sion can be found in the mutant grafts by Western blot analysis
(Figure 2C, insert), most likely attributable to the wild-type
UGSMcells used for reconstitution. Importantly, lentivirus-medi-
ated gene expression in Pten null grafts restored NKX3.1 protein
levels so that they were comparable to those of the WT graft
(Figure 2C, insert). The fact that NKX3.1 protein expression can
be restored andmaintainednear thewild-type levels via anexog-
enous promoter suggests that PTENmodulatesNKX3.1 function
largely through regulation of its transcription, e.g., by controlling
its promoter activity.
Introducing Nkx3.1 into Pten null prostatic epithelium
leads to reduced graft growth
To evaluate the effects of PTEN loss and forced NKX3.1 expres-
sion, we quantified the graft weight (Figure 2C, upper panel) and
DNA contents (Figure S2). To increase the confidence of our
analysis, we considered only the epithelial compartment, in-
stead of both themesenchymal and epithelial ones, as a function
of PTEN loss or forced Nkx3.1 expression (Figure 2C, lower
panel). Compared to wild-type grafts (blue), Pten null grafts (in
red) are significantly larger and include greater number of epi-
thelium (Figure 2C, left, compare wild-type-GFP and Mut-GFP
groups) while forced Nkx3.1 expression consistently reduced
Pten null graft weight and epithelial cell numbers (Figure 2C,
compare Mut-GFP and Mut-Nkx3.1 grafts; p < 0.05). To evalu-
ate whether the effect of forced Nkx3.1 expression dependsCANCER CELL MAY 2006on the stage of cancer, epithelium from PIN lesions (6W) were
harvested and yielded similar observations (Figure 2C, right).
No significant difference was observed when mock-infected
wild-type grafts were compared to Nkx3.1-infected wild-type
grafts (Figure 2C, compare wild-type-GFP and wild-type-
Nkx3.1 groups). These data show that forced Nkx.3.1 expres-
sion can reverse the growth advantage of Pten null epithelium
but has little effects on its wild-type counterpart.
Nkx3.1 blocks Pten null prostate cancer initiation
and progression
Histological analysis indicated that wild-type and Pten null
epithelium reconstituted prostate grafts recapitulate the
Figure 2. Overexpression ofNkx3.1 reduces the growth of reconstituted Pten
null epithelium graft
A: The lentivirus FUGW-IRES-eGFP vector used for expressing Nkx3.1.
B: NKX3.1 expression can be indirectly detected by the expression of GFP
from the same vector (left panels). Right panels show the expression of
Flag-tagged NKX3.1 protein in 293T cells (upper row) and infected, eGFP-
sorted cells (middle row) by Western blot analysis.
C: A comparison of the wet weight (upper panel) and relative epithelial cell
number (lower panel) of regenerated tissue without or with forced Nkx3.1
expression (mean 6 SD). Similar results were obtained in three independent
experiments (p % 0.05). Insert: Western blot shows the levels of PTEN and
NKX3.1 in mock-infected (GFP group) and NKX3.1 viral-infected (Nkx3.1
group) grafts.369
A R T I C L EFigure 3. Nkx3.1 reexpression in Pten null epithe-
lium leads to decreased cell proliferation, in-
creased cell death, and reverse of hyperplasia
phenotype
A–D: Histopathology of regenerated grafts. H&E-
stained paraffin sections of grafts generated
from 4-week-old wild-type (A and B) and Pten
null (MUT) epithelium (C and D). Circled area in
D appears hyperplastic in otherwise normal
duct.
E–L: Consecutive sections from upper panels
were double immunofluorescent stained with
anti-Ki67 and -NKX3.1 antibodies (E–H), as well
as anti-PTEN and -P-AKT antibodies (I–L) and
then counterstained with DAPI. Circled area
shows negative correlation of P-AKT staining (L)
with NKX3.1 expression (H).
M and N: Nkx3.1 reexpression in Pten null epithe-
lium leads to quantitatively decreased cell prolif-
eration (M) and increased cell death (N). Data
are represented as mean 6 SD from three inde-
pendent experiments (p% 0.05).histological characterization of the donor epithelium (Figures 3A
and 3C)(Wang et al., 2003). No significant difference was ob-
served when comparing wild-type-GFP and wild-type-Nkx3.1
grafts (compare Figures 3A and 3B). In contrast, tissue recombi-
nants from Pten null epithelium resulted in very differential phe-
notypes: those from the GFP group demonstrated hyperplasia
and early mPIN lesions, whereas grafts from the Nkx3.1 expres-
sion group showed relative preservation of normal prostatic
duct structure with protein secretion in the lumen (compare Fig-
ures 3C and 3D). Occasionally, isolated areas with hyperplastic
phenotype were observed (Figure 3D, circled area). Further
studies using consecutive sections suggest that these hyper-
plastic lesions are most likely due to incomplete viral infection,
as evidenced by the low to undetectable NKX3.1 protein expres-
sion and high P-AKT staining in the same region (circled areas in
Figures 3H and 3L, respectively). These results suggest that
forced Nkx3.1 expression can rescue the hyperplastic pheno-
type caused by PTEN loss.
Forced Nkx3.1 expression leads to decreased cell
proliferation and increased apoptosis of Pten null grafts
Previous studies showed that overexpression of NKX3.1 in
human PC3 prostate cancer cells and rodent AT 6 cells leads
to inhibition of cell growth (Kim et al., 2002a), whereas increased
epithelial cell proliferation is observed in Nkx3.1 knockout370mice (Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999; Magee
et al., 2003; Tanaka et al., 2000). We examined whether forced
Nkx3.1 expression could inhibit cell proliferation in Pten null
epithelium grafts. Detection of the Ki-67 epitope indicated that
Nkx3.1 expression significantly decreased the proliferative in-
dex of 4W and 6W mutant grafts (compare Figures 3G and
3H; quantification shown in Figure 3M; p % 0.05) consistent
with the growth-suppressive function of NKX3.1 in previous
studies. Interestingly, Pten null epithelium appears to be hyper-
sensitive to NKX3.1’s suppression effect, since NKX3.1 at
similar protein levels (Figure 2C, insert) has no significant effect
on cell proliferation in the wild-type grafts (Figures 3E, 3F,
and 3M).
Given that Pten null grafts infected with NKX3.1 were consis-
tently smaller than those of the control GFP group (Figure 2C),
the apoptotic index was evaluated by way of the TUNEL assay.
In both 4W and 6W Pten null grafts, a significant increase in
TUNEL-positive cells was observed in the presence of NKX3.1
(Figure 3N; p % 0.05). When consecutive tissue sections were
probed for the presence of NKX3.1, TUNEL-positive cells were
consistently associated with areas of strong NKX3.1 expression
(Figure S3). No increase in TUNEL-positive cells was observed
in 4W or 6W wild-type grafts (Figure 3N). Taken together, our
data demonstrate that the effects of NKX3.1 on cell proliferation
and cell death depend on the PTEN status.CANCER CELL MAY 2006
A R T I C L EFigure 4. NKX3.1 negatively regulates AR pro-
moter and modulates AKT phosphorylation
through an AR-dependent mechanism
A: NKX3.1 regulates AR transcription and re-
duces AKT phosphorylation in vitro. Total RNA
and protein were harvested from PTEN-CaP2
cells transfected with Nkx3.1. RT-PCR (upper
panel), and Western blot analysis (lower panel)
was performed as indicated.
B: NKX3.1-regulated AKT phosphorylation de-
pends on AR expression. PC3 cells were trans-
fected with Nkx3.1 without AR (left two lanes)
and with AR (right two lanes). Cell lysates were
immunoprecipitated with indicated antibodies
and analyzed by Western blotting. P-AKT levels
were normalized to actin levels.
C: Loss of NKX3.1 leads to increased AR expres-
sion in vivo. Western blot analysis of wild-type
and Nkx3.1 null prostate tissues. AR expression
levels were normalized to actin loading control.
D: NKX3.1 regulates AR expression in normal hu-
man primary prostatic cells. PrEC cells were
transfected with indicated plasmid. Thirty-six
hours later, RNA and protein were harvested for
real-time PCR (upper panel) and Western blot
analysis (lower panel), respectively. AR expres-
sion and NKX3.1 expression levels were normal-
ized to actin levels.
E: NKX3.1 suppresses AR transcription. PTEN-CaP2
cells were cotransfected with AR luciferase re-
porter constructs and NKX3.1 expression vector.
Relative AR transcriptional activity was mea-
sured 24 hr posttransfection. Three independent
tests were performed for each experiment and
presented as mean 6 SD.
F:Association of endogenous NKX3.1 with the AR
promoter. LNCaP cells were treated with or with-
out DHT (10 nM) for 16 hr, and ChIP analysis was
performed according to Experimental Proce-
dures.NKX3.1 negatively regulates AKT activity
in an AR-dependent manner
To investigate possible changes in the known PTEN-controlled
signaling pathways in the presence and absence of NKX3.1,
we first examined AKT status on consecutive sections of the
grafts. No difference in either PTEN or P-AKT levels can be de-
tected in the wild-type grafts with or withoutNkx3.1 overexpres-
sion (Figures 3I and 3J). Robust P-AKT staining can be detected
in themock-infected Pten null grafts (Figure 3K), whereas forced
Nkx3.1 expression, at a level comparable to that of wild-type
prostatic epithelium (compareFigures3Fand3H,andFigure2C),
leads to a dramatic decrease in P-AKT levels (Figure 3L). In the
uninfected area where NKX3.1 staining is weak or undetectable
(Figure 3H, circled area), P-AKT level remains high, thus serving
as an important internal control (Figure 3L, circled area).
To develop a system more amenable to in vitro biochemical
analysis, we generated several prostate epithelial cell lines
from the prostates of Pten conditional knockout mice. One
such line, PTEN-CaP2, is characterized by positive AR expres-
sion but undetectable PTEN and NKX3.1 protein expressionCANCER CELL MAY 2006(our unpublished data). Nkx3.1 overexpression in PTEN-CaP2
cells suppressed AKT phosphorylation by 3-fold (Figure 4A,
lower panel).
Given previous studies that androgen receptor (AR) can mod-
ulate AKT activation via a PI3K-dependent mechanism (Baron
et al., 2004; Sun et al., 2003), we investigated whether AR serves
as a mediator for NKX3.1-regulated AKT activity. For this, we
used PC3 cells, a human prostate cancer cell line known to be
null for AR, PTEN, and NKX3.1. When we compared P-AKT
levels in the presence or absence of NKX3.1 without cotransfec-
tion of AR, we did not detect any significant difference (Fig-
ure 4B, first two lanes in the upper panel). While introduction
of AR significantly increased the level of P-AKT (Figure 4B, com-
pare first and third lanes in the upper panel), this effect was di-
minished by cotransfection of the Nkx3.1-expressing vector
(Figure 4B, compare the third and fourth lanes). Previous studies
also showed that ARmodulatesAKTphosphorylation via binding
of the p85a subunit of PI3-kinase (Baron et al., 2004; Sun et al.,
2003). We performed reciprocal coimmunoprecipitation experi-
ments and showed that Nkx3.1 overexpression decreases the371
A R T I C L EamountofARable to interactwithp85a (Figure 4B, lowerpanels),
further supporting the notion that NKX3.1 controls AKT phos-
phorylation via an AR/PI3K-dependent mechanism.
NKX3.1 negatively regulates the AR promoter
Since AR serves as a mediator for NKX3.1-controlled AKT acti-
vation, we investigated the possible role of NKX3.1 on AR ex-
pression in the PTEN-CaP2 cells and found that NKX3.1 also in-
hibits AR expression at both mRNA (Figure 4A, upper panel) and
protein levels (Figure 4A, lower panel). To determine if NKX3.1
negatively regulates AR in vivo, we examined AR protein levels
in the prostate glands of Nkx3.1 knockout mice (Kim et al.,
2002b) and found thatAR levelsare indeed increased (Figure4C).
The role of NKX3.1 in negatively regulating AR level was also
confirmed in human primary prostatic PrEC cells (Figure 4D,
upper panel; compare lanes 2 and 4 in the lower panel).
Similar to previous reports (Bieberich et al., 1996; He et al.,
1997; Magee et al., 2003; Prescott et al., 1998), our study indi-
cates that NKX3.1 expression can be positively modulated by
androgen (Figure 4D, compare lanes 3 and 4; Figure 6B). That
overexpression of NKX3.1 leads to AR downregulation (upper
panels in Figures 4A and 4D) while NKX3.1 loss results in an in-
creased level of AR (Figure 4C) suggests that AR and NKX3.1
may form an important feedback loop. Within this feedback
loop, NKX3.1 may serve as an important negative regulator for
AR expression as well as AR-controlled signaling pathway. To
test this hypothesis, we searched sequences surrounding the
murine AR promoter region and found a potential NKX3.1 con-
sensus binding site, TAAGTA, within the 50 UTR. The functional
significant of this consensus site was further investigated using
a series of luciferase reporter constructs with truncated pro-
moter regions (Figure 4E, upper panel). NKX3.1 significantly
suppressed the wild-type reporter construct, while it had little
effect on a D315 construct in which sequences surrounding
the putative binding motif have been deleted (Figure 4E, lower
panel). Changing ‘‘TAAGTA’’ to ‘‘TAAAAA’’ also decreased
NKX3.1’s effect (Figure 4E, lower panel).
To assess whether NKX3.1 can associate with the endoge-
nous AR promoter, we conducted chromosome immunoprecip-
itate (ChIP) analysis on the human prostate cancer cell line
LNCaP, which expresses endogenous NKX3.1 and AR. Using
a primer set that contains the human NKX3.1 ‘‘CAAG’’ motif
(nt 1223–1386), we showed that the endogenous NKX3.1 can
physically associate with the AR promoter and that this associ-
ation can be further enhanced in the presence of androgen
(Figure 4F, primer 2). We further demonstrate that this associa-
tion is site specific: primer 1 set derived from nt 1113–1311 of
the human AR promoter containing the ‘‘CAAG’’ motif, as well
as control primers (nt 17–170) without the CAAG motif, can
not detect NKX3.1 binding activity. Therefore, NKX3.1 inhibits
AR transcriptional activity, at least in part, through its consensus
binding site.
NKX3.1 negatively regulates AR expression in both
murine and human prostatic cancer samples
To test whether the inverse relationship betweenNKX3.1 andAR
is present in human prostate cancer samples, we conducted
double immunofluorescent analysis ofNKX3.1 andARand found
two basic scenarios: areas where NKX3.1 levels negatively
correlate with AR levels (Figure 5A) and areas where NKX3.1
and AR are coexpressed (Figure 5B). Interestingly, even in the372areas where both NKX3.1 and AR are expressed, mosaic pat-
terns of NKX3.1 and AR expression can be easily detected
(Figure 5B, high-powered image on the right), suggesting that
the NKX3.1-AR feedback loop may function at a single cell level.
Importantly, despite upregulated AR levels (Figure 5C),
NKX3.1 mRNA levels are downregulated in both PIN (Figure 5C)
and Pten null prostate cancer (Wang et al., 2003), suggesting
that PTEN either plays a predominant role over AR, the known
positive regulator of Nkx3.1, or is essential for AR-mediated
Nkx3.1 regulation. We then compared the relative expression
levels of those NKX3.1 target genes identified by Magee et al.
(2003) that are also present in our microarray data sets (Wang
et al., 2003 and our unpublished data). Intriguingly, the trends
of gene regulation in the Pten null prostate are very similar to
what has been observed in the Nkx3.1 null prostate: Probasin,
which is known to be positively regulated by NKX3.1, is down-
regulated in thePtennull PIN lesions,whereasElafin-like II,which
belongs to the repression group, is upregulated upon Pten dele-
tion (Figure 5C). Furthermore, the mosaic expression patterns of
NKX3.1 and AR shown in Figure 5B may provide an explanation
for the stochastic expression patterns of NKX3.1-targeted
genes within the same prostatic acini (Magee et al., 2003).
NKX3.1 stabilizes p53 through MDM2-dependent
and AKT-independent mechanisms
PTEN regulates p53 protein levels and transcription activity via
AKT-MDM2-dependent and -independent mechanisms (Free-
man et al., 2003; Mayo and Donner, 2001; Zhou et al., 2001).
The fact that overexpression of NKX3.1 inhibits AKT phosphor-
ylation in Pten null grafts prompts us to analyze whether NKX3.1
also alters p53 levels. Western blot analysis demonstrated that
forced Nkx3.1 expression significantly increases p53 protein
levels in Pten null grafts in vivo (Figure 6A, upper panels),
whereas knockout of Nkx3.1 leads to reduced p53 levels (Fig-
ure 6A, lower panels).
To understand the molecular mechanisms involved in
NKX3.1-regulated p53 activity, we first measured endogenous
p53 levels in the LNCaP cells. The androgen analog R1881
can stimulate the endogenous NKX3.1 expression with a peak
around 4 hr (Figure 6B, upper panel). Following this trend, p53
protein levels are also increased by 1.5-fold 4 hr after R1881 ad-
dition (Figure 6B, upper panel). Consistently, overexpression of
Nkx3.1 leads to increased p53 protein levels without changing of
its mRNA level (Figure S4, upper panel), suggesting that NKX3.1
modulates p53 at the posttranscriptional level. Furthermore,
Nkx3.1 expression leads to an increase in p53 half-life from 21
min to 30 min in LNCaP cells (Figure 6B, lower panel). Similar re-
sults were also obtained when using the Pten null murine PTEN-
CaP2 prostate cancer cell line (Figure S4, lower panel).
To determine whether NKX3.1 stabilizes p53 in a MDM2-de-
pendent manner, we introduced Nkx3.1 into p53/Mdm2 double
null (p532/2;Mdm22/2) mouse embryonic fibroblasts (Jones
et al., 1995).WithoutMDM2, NKX3.1 has no significant influence
on p53 expression levels (Figure 6C, compare lanes 3 and 4).
When cotransfected with a vector containing Mdm2, NKX3.1
expression partially reverses the increased p53 degradation
brought about by Mdm2 overexpression (Figure 6C, compare
lanes 5 with 6), suggesting that NKX3.1 controls p53 half-life
via a MDM2-dependent mechanism.
MDM2 nuclear translocation and stability are known to be
controlled by AKT phosphorylation (Mayo and Donner, 2001;CANCER CELL MAY 2006
A R T I C L EFigure 5. NKX3.1 controls AR level in human prostate cancers and modulates its target gene expression in Pten null prostate cancer model
A: Inverse correlation of NKX3.1 and AR levels in human prostate cancer samples. Representative images of double immunohistochemistry analysis using anti-
NKX3.1 and AR antibodies.
B:Mosaic expression patterns of NKX3.1 and AR in human prostate samples. Double immunohistochemical analysis shows overlapping NKX3.1 and AR expres-
sion in most of the epithelial cells (in yellow), with some cells that have higher levels of either NKX3.1 (in red; red arrowheads) or AR (in green; white arrowheads)
expression.
C: The relative expression levels of Nkx3.1, AR, and their target genes in Pten-deleted prostate glands. Microarray analysis was performed using mRNA pre-
pared from the prostates of 6-week-old Pten null mice (PIN lesion stage) and their wild-type littermates (n = 5). Fold of changes in indicated genes was
calculated as the relative expression levels of PIN versus wild-type (p% 0.01).Zhou et al., 2001). To determine whether NKX3.1 antagonizes
MDM2 function via an AKT-dependent mechanism, we treated
PC3 cells with or without LY294002, a specific inhibitor for
PI3K. As shown in Figure 6D, although P-AKT levels were signif-
icantly diminished, LY294002 treatment had no significant effect
on either p53 (compare lanes 2 and 5) or NKX3.1-regulated p53
level (compare lanes 3 and 6). This result suggests that NKX3.1
regulates p53 half-life by modulating nuclear MDM2 activity,
independent of AKT activation.
NKX3.1 can physically associate with HDAC1
and promotes p53 acetylation by recruiting HDAC1
from p53-MDM2-HDAC1 complex
Besides its E3 ubiquitin ligase activity, MDM2 can negatively
regulate p53 half-life by recruiting a nuclear protein HDAC1,
thereby promoting p53 deacetylation and degradation (Kobet
et al., 2000; Ito et al., 2002; Brooks and Gu, 2003). To determine
if enhanced p53 acetylation is one of the mechanisms involved
in NKX3.1-mediated p53 half-life control, we examined acety-
lated p53 levels without or with Nkx3.1 overexpression andCANCER CELL MAY 2006found that NKX3.1 indeed enhances p53 acetylation (Figure 6E,
upper panel). In vivo, NKX3.1 can physically associate with ei-
ther endogenous or exogenous HDAC1 (Figure 6E, middle and
lower panels), suggesting that NKX3.1 can form a complex
with HDAC1 and change p53 acetylation status. Furthermore,
NKX3.1 cannot further increase p53 levels in the presence of
TSA, an inhibitor for HDAC activity, suggesting that NKX3.1
indeed depends on HDAC activity to regulate p53 level
(Figure S5).
We then tested whether NKX3.1 can recruit HDAC1 from p53-
MDM2-HDAC1 complex. To do this,Mdm2 was introduced into
p532/2;Mdm22/2 cells, without or with Nkx3.1, followed by
measurement of the relative amount of p53 associating with
HDAC1. It was observed that Mdm2 expression leads to in-
creased p53-HDAC1 association by 4-fold, resulting in de-
creased total p53 protein level (compare lanes 1 and 2 of
Figure 6F). In contrast, coexpressing Nkx3.1 reduces p53-
HDAC1 association, partially rescuing MDM2-mediated p53
degradation (Figure 6F, compare lanes 2 and 3). Thus, NKX3.1
regulates p53 half-life, as least in part, by recruiting HDAC1373
A R T I C L EFigure 6. NKX3.1 regulates the level of p53 in
a MDM2-dependent and AKT-independent
manner
A:NKX3.1 regulates the level of p53 in vivo. Upper
panel: reintroducing Nkx3.1 into Pten null epithe-
lium increases p53 protein level in regenerated
grafts. Lower panel: knocking out Nkx3.1 leads
to decreased p53 protein levels. Cell lysates
from Nkx3.1 wild-type and null prostate tissues
were analyzed using Western blot and normal-
ized to actin loading control.
B:NKX3.1 regulated p53 level and half-life. Upper
panel shows androgen-induced NKX3.1 expres-
sion and p53 increase in LNCaP cells. Lower
panel: Nkx3.1-transfected LNCaP cells were in-
cubated with cycloheximide for the indicated
time, and total proteins were analyzed by West-
ern blot. p53 half-life was calculated using Quan-
tity One (Bio-Rad).
C: NKX3.1 stabilizes p53 via MDM2-dependent
mechanism. Western blot analysis of cell lysates
from p532/2;Mdm22/2 MEFs after transfection
of indicated plasmids.
D: NKX3.1 stabilizes p53 in an AKT-independent
manner. PC3 cells were transfected with indi-
cated plasmids with or without LY treatment be-
fore harvesting. Cell lysates were analyzed by
Western blot.
E: NKX3.1 increases p53 acetylation and can
physically associate with HDAC1. Upper panel:
LNCaP cells were transfected without or with
Nkx3.1, and the cell lysates were first immunopre-
cipitated with anti-p53 antibody and then blot-
ted with antibodies recognizing either acety-
lated p53 or total p53, respectively. Middle
panel: LNCaP cells were treated with androgen
analog R1881 for 4–6 hr to induce Nkx3.1 expres-
sion, and cell lysates were immunoprecipitated
with anti-NKX3.1 antibody and then blotted with
indicated antibodies. Lower panel: LNCaP cells
were cotransfected with Flag-tagged HDAC1
and myc-tagged NKX3.1. Cell lysates were immu-
noprecipitated with either anti-Flag or control
IgG and blotted with anti-myc antibody.
F:NKX3.1 modulates the level of p53 by recruiting
HDAC1 from the MDM2-p53 complex. PC3 cells
were cotransfected with indicated plasmid.
Cell lysates were immunoprecipitated with anti-
HDAC1 antibody and blotted with anti-p53 anti-
body. The relative amounts of p53 within the p53-
HDAC1-MDM2 complex, as indicated above the
Western blot, were calculated as HDAC1-associ-
ated p53:total p53 from the input, then normal-
ized against lane 1.from the HDAC1-MDM2-p53 complex, thereby promoting p53
acetylation.
Discussion
The involvement of NKX3.1 in human prostate cancer develop-
ment has been intensively studied since its cloning (for review
see Abdulkadir, 2005). Despite strong correlation of loss of
NKX3.1 expression in human prostate cancer initiation and pro-
gression, several outstanding questions remain to be answered;
these include but are not limited to the following. (1) How and at
what level is NKX3.1 expression controlled in the prostate epi-
thelium? (2) What is the normal function of NKX3.1 in vivo?
And (3) what are the targets of NKX3.1, and how do those374targets, upon NKX3.1 loss, contribute to prostate cancer initia-
tion and progression? Our current study suggests that PTEN
and its controlled signal pathway regulate NKX3.1 expression
in the prostatic epithelium. Within the prostate epithelium, AR
and NKX3.1 form a signaling feedback loop in which NKX3.1
is the negative modulator that keeps AR level and AR-controlled
pathways in check. NKX3.1 regulates prostate cell proliferation
and survival not only via its transcription factor activity, i.e., by
negatively modulating the AR promoter, but also through pro-
tein-protein interaction with HDAC1 and consequently regulat-
ing p53 half-life and activity (Figure 7). Our finding emphasizes
the cooperative effects between ubiquitously expressed PTEN
tumor suppressor genes and prostatic-specific expressed
NKX3.1 in prostate cancer development.CANCER CELL MAY 2006
A R T I C L EFigure 7. A schematic diagram illustrating the involvement of NKX3.1 in PTEN-controlled prostate tumorigenesis
In Pten wild-type prostatic epithelium (left panel), PTEN negatively regulates PI3K/AKT pathway but positively modulates p53 level and activity. The transcrip-
tion level of Nkx3.1 is controlled predominantly by PTEN as well as by AR. NKX3.1 in turn negatively regulates AR promoter activity and keeps AR and AR-con-
trolled pathway in check. NKX3.1 also binds HDAC1 and releases p53 from p53-MDM2-HDAC1 complex, promoting p53 acetylation and activity. The net result
of these NKX3.1-mediated PTEN functions is the balanced cell proliferation, differentiation, and cell death, which prevents prostate cancer initiation. Upon
PTEN loss (right panel), the balance is broken, and NKX3.1 and its controlled signaling pathways are severely downregulated. AR, no longer under the control
of NKX3.1, becomes overexpressed and activates its targets and downstream pathways, including PI3K/AKT pathway. In the absence of NKX3.1, most of the
p53 is in the MDM2-HDAC1 complex, leading to p53 degradation. Activation of PI3K/AKT pathway, together with downregulated p53 activity and increased
AR level and activity, leads to increased cell proliferation, decreased cell death, and prostate cancer initiation.Several mechanisms have been proposed for loss of NKX3.1
expression in human prostate cancers, including both posttran-
scriptional modification, such as protein degradation, as well as
transcriptional and epigenetic regulation (Asatiani et al., 2005;
Bowen et al., 2000; He et al., 1997; Korkmaz et al., 2004; Orn-
stein et al., 2001; Voeller et al., 1997). The facts that NKX3.1
mRNA (Figure 5C and Wang et al., 2003) and protein levels
(Figure 1A and Wang et al., 2003) are concomitantly downregu-
lated in the Pten null prostate, and we can successfully restore
Nkx3.1 expression using an exogenous promoter and maintain
near wild-type levels of NKX3.1 in different cell lines and in the
renal capsule grafts (Figure 2C), suggest that PTEN modulates
NKX3.1 function largely through regulation of its promoter activ-
ity. This conclusion is consistent with the strong correlation of
NKX3.1 mRNA and protein levels in human prostate cancer
specimens reported by a recent study (Korkmaz et al., 2004).
Nkx3.1 is positively regulated by androgen and its receptor AR
at the transcriptional level (Bieberich et al., 1996; He et al., 1997;
Magee et al., 2003; Prescott et al., 1998). Our results suggest
that PTEN either predominantly controls NKX3.1 transcription
or contributes significantly to AR-controlled mechanism. In the
presence of PTEN, Nkx3.1 expression can be modulated by
AR, while in its absence,Nkx3.1 expression is almost completely
silenced despite increases in AR levels in Pten null prostate
cancers (Wang et al., 2003; Figures 1A, 5C, and 7). Mechanisms
involving enhancer/promoter and transcription activator/repres-
sor interactions, epigenetic changes such as DNA methylation
(Asatiani and Gelmann, 2005), and histone modification (Plass,
2002) are all potential possibilities by which NKX3.1 and AR in-
teract and are regulated by PTEN and warrant a separate and
more elaborate study.
Recently, Magee et al. identified NKX3.1 target genes that are
sensitive to NKX3.1 dosage in a stochastic manner and, at theCANCER CELL MAY 2006same time, are influenced by the androgen status in vivo (Magee
et al., 2003). Among those target genes is a set regulated by an-
drogens only in the absence of NKX3.1, suggesting that NKX3.1
functions as a selector for modulation of the expression of
potential androgen target genes. We demonstrate that NKX3.1
loss, in either human prostate cancer samples (Figure 5A) ormu-
rine prostates of Pten and Nkx3.1 knockout mice (Figures 5C
and 4C), leads to increased AR levels. Conversely, overexpres-
sion ofNkx3.1 decreases ARmRNA and protein expression (Fig-
ures 4A and 4D). These results imply that NKX3.1 is a negative
regulator for AR expression, and AR and NKX3.1 form a feed-
back loop important for both prostate development and cancer
formation. With Nkx3.1 at steady-state levels, androgen/AR in-
duces NKX3.1 expression, which in turn inhibits AR expression.
Interestingly, the mosaic expression pattern of NKX3.1/AR tar-
get genes showed by Magee and colleagues (Magee et al.,
2003) are similar to NKX3.1 and AR expression patterns ob-
served in human prostate samples (Figure 5B), suggesting that
the balance of NKX3.1-AR expression may ultimately determine
the levels of target gene expression. The natural ‘‘set point’’ of
this feedback loop and its range of action are currently unknown
and require further investigation. Loss of NKX3.1 in the prostatic
epithelium will impair this feedback system (Figure 7), which in
turn leads to AR overexpression and may contribute to PIN
lesion in Nkx3.1 knockout mice (Abdulkadir et al., 2002; Kim
et al., 2002a) and prostate cancer development in Pten null
model (Wang et al., 2003), similar to what has been concluded
fromAR transgenic animals (Stanbrough et al., 2001) and human
prostate cancer studies (Chen et al., 2004).
The growth-suppressive activities of NKX3.1 have been dem-
onstrated in vitro in cell culture system and in vivo in knockout
mice (Bhatia-Gaur et al., 1999; Kim et al., 2002a; Schneider
et al., 2000; Tanaka et al., 2000). NKX3.1 haploinsufficiency or375
A R T I C L Eloss leads to significant delay in exiting from the cell cycle
(Magee et al., 2003), but how NKX3.1 engages the cell cycle
machinery to regulate prostatic epithelium growth is currently
unknown. Here, we showed that restoration of Nkx3.1 expres-
sion to the wild-type level in Pten null prostatic epithelium leads
to increased p53 protein levels in vivo and in vitro. NKX3.1 can
physically associate with HDAC1 and recruit HDAC1 from the
HDAC1-MDM2-p53complex, protectingp53 fromdeacetylation
and degradation. Furthermore, NKX3.1 stabilizes p53 through
modulation of MDM2 activity in the nucleus, independent of
AKT-mediated MDM2 phosphorylation and nuclear transloca-
tion. Whether the above-mentioned pathways involve or collab-
orate with NKX3.1-regulated oxidative damage or p53-depen-
dent senescence requires further investigation (Chen et al.,
2005; Ouyang et al., 2005).
Although this study suggests that NKX3.1 plays an essential
role in PTEN-controlled prostate cancer development, NKX3.1
loss alone only mimics a part of Pten deletion phenotype, sug-
gesting that other PTEN-controlled pathways may synergisti-
cally interact with those NKX3.1-dependent events (Figure 7).
AKT hyperphosphorylation has been observed in isolated clus-
ters of cells within regions of high grade PIN lesions inNkx3.1+/2
and Nkx3.12/2mice, and deletion of one allele of Pten in Nkx3.1
null mice leads to accelerated tumor initiation and increased in-
cidence of high-grade PIN (Kim et al., 2002b). However, differing
from the Pten null prostate cancer model (Wang et al., 2003),
Pten+/2;Nkx3.12/2 mice do not progress to metastatic prostate
cancer (Kim et al., 2002b). These results suggest that the dos-
age of PTEN plays a dominant role in the cooperative effect of
NKX3.1 and PTEN.
We showed that forced Nkx3.1 expression in Pten null epithe-
lium significantly induces cell apoptosis in the mutant grafts.
This mechanism, together with NKX3.1’s growth suppression
function, leads to reduced graft size. Interestingly, the effects
of NKX3.1 appear to depend on the PTEN status: Nkx3.1 over-
expression leads to increased cell death and decreased cell
proliferation in the Pten null grafts but has no significant impact
on the wild-type grafts. One possible explanation is that Pten
null cells have become ‘‘addicted’’ to high levels of PI3K/AKT
activity and, consequently, are hypersensitive to inhibition of
this pathway. We have previously shown that PTEN-deficient
human cancer cell lines and murine Pten null tumors are sensi-
tive to inhibitors specific formTOR, a downstream effector of the
PI3K/AKT pathway (Neshat et al., 2001). In the present study, we
demonstrate that NKX3.1 inhibits AKT phosphorylation/activa-
tion via an AR-dependent mechanism and show that NKX3.1
expression in vivo can block the hyperproliferative and antia-
poptotic effects brought on by PTEN loss. This mechanism elu-
cidates a pathway that can potentially be targeted with specific
therapies for human prostate cancer, given that 30% of primary
prostate cancers and as many as 60% of metastatic cases ex-
hibit PTEN LOH (Sellers and Sawyers, 2002).
Experimental procedures
Immunohistochemical analysis
Tissues were fixed in 10% buffered Formalin for 6 hr, followed by transfer to
70% alcohol. These paraffin-embedded tissues were sectioned (4 mm) and
stained with hematoxylin and eosin. Antigen retrieval was performed by incu-
bating the slides in 0.01 M citric acid buffer (pH 6.0) at 95ºC for 30 min. The
endogenous peroxidase activity was inactivated in a solution containing
3% hydrogen peroxide (H2O2) in methanol. The following detection and376visualization procedures were performed according to the manufacturer’s
protocol. Negative control slides were performed without primary antibody.
Control slides known to be positive for each antibody were incorporated.
For fluorescence double staining, pretreated sections were first blocked
with mouse Ig blocking reagent in the VECTOR M.O.M. Immunodetection
Kit (Vector Laboratories) and then incubated with mouse antibody PTEN
(26H9, Cell Signaling Technology), Ki67 (NCL-Ki67-MM1), or NKX3.1 (a
kind gift from Dr. Abate-Shen) at room temperature for 30 min, followed by
signal amplification with TSAPlus Fluorescence Systems (PerkinElmer). After
biotin blocking, the section was then stained with rabbit antibody P-AKT
(9277, Cell Signaling Technology) or AR (PG21, Upstate), and signal was am-
plified with TSA system with different fluorescence. For human prostate
tissue array, PTEN, NKX3.1 (SC-816 and SC-15022, Santa Cruz), and AR
(PG21, Upstate) were used.
Tissue array analysis
Double immunofluorescent staining was performed as above. PTEN and
NKX3.1 (Santa Cruz SC-816 and SC-15022, respectively) intensity was ana-
lyzed by Image Plus software, and only cores with epithelial structure were
chosen for further analysis. Briefly, we chose four views for each core; mea-
sured the signal intensity using Image Plus software; and signed the signal
intensity as 0–6, in which 0[<50]; 1[50-75]; 2[75–100]; 3[100–125]; 4[125–
150]; 5[150–175]; 6[>175]. According to the average intensity value, samples
were categorized into grades. By using the intensity grade, a stacked line
was generated with value of each sample displayed. Linear regression anal-
ysis was performed for the correlation between PTEN and NKX3.1 expres-
sion by SPSS software and presented as Skattergram.
Preparation of prostate epithelial cells, virus infection,
and prostate regeneration
Four- and six-week-old Pten wild-type and mutant mice were killed by car-
bon dioxide inhalation. Prostates were dissected, cut into small pieces
with a steel blade, and digested with 0.8 mg/ml collagenase (GIBCO, 226
units/mg) in 10 ml of DMEM 10% FBS (GIBCO) at 37ºC for 90 min. Cells
were filtered through 100 mm nylon mesh (Becton Dickinson), washed twice
with 10 ml of DMEM 10% FBS, resuspended in 1 ml of DMEM 10% FBS, and
counted.
The lentivirus was prepared as described (Lois et al., 2002; Pfeifer et al.,
2002). Infection was carried out according to Xin et al. (2003). Briefly, 1 3
105 prostate cells were mixed with GFP or NKX3.1 Lentivirus stock (titer
2 3 107) in the presence of 8 mg/ml polybrene (Sigma), then centrifuged at
1500 rpm with a Beckman GS-6R centrifuge (Beckman Coulter) for 2 hr at
room temperature and washed twice with 1 ml of DMEM 10% FBS. All pro-
cedures were performed under University of California Los Angeles safety
regulations for lentivirus usage.
Mouse prostate regeneration was performed according to previous
reports (Cunha and Donjacour, 1987; Thompson et al., 1989; Xin et al.,
2003). Lentivirus-infected cells (1 3 105) were combined with UGSM cells
(13 105) and 25 ml of type I collagen (Roche) and then grafted under the renal
capsule. Each experiment contained grafts of UGSM alone to ensure that tis-
sue growth did not result from contaminating urogenital sinus epithelial cells.
Grafts were harvested and weighed after 6–9 weeks. All surgical procedures
were performed under Division of Laboratory Animal Medicine regulations of
the University of California, Los Angeles.
Cell proliferation and apoptosis index
Cell proliferation index was examined by Ki67 staining. Five different fields
were chosen, and then 200 cells were counted in each field. Ki67+ cells
were presented as the percentage of nucleated cells. Cell apoptosis were de-
termined by TUNEL assay using the In Situ Cell Death Detection Kit from
Roche according to the manufacturer’s instruction. Sections were dewaxed
with xylene and rehydrated through graded alcohol. DNA fragmentation was
labeled with fluorescein-conjugated dUTP and visualized with fluorescence.
TUNEL-positive cells were counted and presented the percentage of nucle-
ated cells.
Western blot analysis
Protein lysate was prepared by sonicating graft tissues and prostate tissue
from Nkx3.1 mice, R1881 treated or transfected LNCaP, PC3 and PTEN-
CaP2 cells in buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl,CANCER CELL MAY 2006
A R T I C L E0.1% SDS, 0.5% SD, 1%NP-40, 1 mMEDTA, 1 mMPMSF, 25 mMNaF, and
cocktail protease inhibitors (Roche). Tissue lysate (40 mg) was resolved to
SDS-PAGE followed by Western blot analysis using anti-p53 (Ab-1, Onco-
gene; DO-1, Santa Cruz), P-AKT (9271, Cell Signaling), total AKT (Cell Signal-
ing), NKX3.1 (SC-15022, Santa Cruz), MDM2 (Ab-2, Oncogene), Flag (Strata-
gene), and Actin (#5060, Sigma) antibodies, respectively.
For immunoprecipitation experiments, 500 mg of cell lysate was incubated
16 hr at 4ºC with 2 mg AR or p85a antibody (PG-21 and #06-496, Upstate),
p53 antibody (DO-1, Santa Cruz), NKX3.1 or HDAC1 (SC-15022, SC-
07872, Santa Cruz), or Flag antibody (Sigma, F1804) plus 50 ml Protein A aga-
rose beads (#16-125, Upstate). Beads were washed three times with lysis
buffer and centrifuged for 5 min at 5000 g between each wash. Protein
was eluted from beads with 50 ml Laemmli sample buffer (Bio-Rad). Lysates
were resolved on a 10% SDS-PAGE gel and transferred onto nitrocellulose
(Bio-Rad).
For endogenous NKX3.1 induction, LNCaP cells were treated with 2 nM
R1881 for different time periods after being plated in 10% charcoal serum
for 2 days. For half-life experiments, NKX3.1 was transfected into LNCaP
cells 36 hr prior to the addition of 50 mg/ml cycloheximide (Cycloheximide,
Calbiochem) in serum-free medium. Cells were then lysed at indicated time
points and further analyzed by Western blot.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
five supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/5/367/DC1/.
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